Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen
October 27 2023 - 11:00AM
In an era marked by relentless change and the pressing need to
adapt, Psychemedics, a pioneer in the drug screening industry,
proudly announces the launch of a revolutionary, Advanced 5-Panel
Drug Screen. This groundbreaking offering will transform the way
organizations safeguard their workplaces, shifting the spotlight
from marijuana to the paramount threat of fentanyl. Complemented by
the detection of cocaine, opioids, PCP, and amphetamines, the
advanced panel is a leap forward in drug screening technology.
As we grapple with an ongoing labor shortage and with
marijuana’s legal landscape evolving in 49 states, it’s clear that
the time for a change has come. Traditional 5-panel drug tests,
rooted in a four-decade-old paradigm, have failed to evolve in
today’s drug market and are unable to detect the rising drug,
fentanyl.
“Few challenges in the workplace have undergone as dramatic a
transformation as the shifting dynamics between marijuana and
fentanyl,” remarked Brian Hullinger, President and CEO at
Psychemedics. “Recognizing this shift, Psychemedics has developed
the Advanced 5-Panel to bridge the gap.”
For decades, Psychemedics has remained at the forefront of
innovation, responding to the ever-evolving needs of our clients.
The Advanced 5-Panel Drug Screen epitomizes this legacy, offering
clients a cost-effective choice to adapt their testing protocols in
sync with evolving priorities and employment policies. More
importantly, it ensures that resources and dollars are invested in
identifying the threats that matter most to organizations
today.
The impact of this offering is not merely theoretical; it is
supported by a recent independent study encompassing nearly 1
million drug tests. The findings demonstrate that hair testing
outperforms traditional methods in detecting the most abused
substances, such as opioids, cocaine, and amphetamines:
- 25 times more effective at detecting opioids.
- 23 times more accurate in identifying cocaine use.
- 13 times more adept at pinpointing amphetamine use.
The Advanced 5-Panel Drug Screen is crafted to focus exclusively
on these critical threats, ensuring the highest level of security
for organizations.
For more information about Psychemedics Corporation and its
innovative hair testing solutions, please visit
https://www.psychemedics.com.
About Psychemedics
Psychemedics Corporation is a leading global provider of
innovative hair testing for drugs of abuse. With a commitment to
accuracy and reliability, the company offers cutting-edge drug
testing solutions. Psychemedics Corporation is dedicated to
providing valuable insights and maintaining the highest standards
in substance abuse testing.
Cautionary Statement for purposes of the “safe
harbor” provisions of the Private Securities Litigation Reform Act
of 1995:
From time to time, information provided by
Psychemedics may contain forward-looking information that involves
risks and uncertainties. In particular, statements contained
in this release that are not historical facts (including but not
limited to statements concerning earnings, earnings per share,
revenues, cash flows, receivables collection dates, dividends,
future business, growth opportunities, new or revised product
offerings (including the Company’s Advanced 5-panel drug screen)
profitability, pricing, new accounts, customer base, market share,
test volume, sales and marketing strategies, market demand for drug
testing services, and new test development, may be
“forward-looking” statements. Actual results may differ from
those stated in any forward-looking statements. Factors that
may cause such differences include but are not limited to, changes
in U.S. and foreign government regulations, including but not
limited to FDA regulations, currency risks, R&D spending,
competition (including, without limitation, competition from other
companies pursuing the same growth opportunities), the Company’s
ability to maintain its reputation and brand image, the ability of
the Company to achieve its business plans, cost controls,
leveraging of its global operating platform, risks of information
technology system failures and data security breaches, the
uncertain global economy, the Company’s ability to attract, develop
and retain executives and other qualified employees and independent
contractors, including distributors, the Company’s ability to
obtain and protect intellectual property rights, litigation risks,
general economic conditions and other factors disclosed in the
Company's filings with the Securities and Exchange Commission. The
forward-looking statements contained herein speak only of the
Company's expectations as of the date of this press
release. The Company expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
such statement to reflect any change in the Company's expectations
or any change in events, conditions, or circumstances on which any
such statement is based.
Investor Relations:Phone:
978-206-8220Email: InvestorRelations@psychemedics.com
Psychemedics (NASDAQ:PMD)
Historical Stock Chart
From Apr 2024 to May 2024
Psychemedics (NASDAQ:PMD)
Historical Stock Chart
From May 2023 to May 2024